NCT04515953View on ClinicalTrials.gov

A Phase I Dose-escalation Study of a Single Administration of Extended-Release Injectable Suspension (ND-340)

PHASE1SuspendedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 15, 2020

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Pain, Postoperative
Interventions
DRUG

ND-340

ND-340: Subjects will receive a single administration of ND-340 at the specified dose in each arm after TKA.

DRUG

IV-PCA

IV-PCA: Intravenous patient-controlled analgesia (IV-PCA), morphine, will be administered in subjects of control group after TKA for postoperative pain management as standard practice.

Trial Locations (1)

712

Nang Kuang Pharmaceutical Co., LTD, Tainan City

Sponsors
All Listed Sponsors
lead

Nang Kuang Pharmaceutical Co., Ltd.

INDUSTRY